Cargando…
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients
BACKGROUND: Coronavirus disease 2019 (COVID-19) continues to stress the health care system. Neutralizing monoclonal antibodies (mAbs) were effective in reducing COVID-19–related hospitalizations and emergency department (ED) visits in their respective clinical trials. However, these results have yet...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195104/ https://www.ncbi.nlm.nih.gov/pubmed/34258319 http://dx.doi.org/10.1093/ofid/ofab292 |
_version_ | 1783706461069639680 |
---|---|
author | Piccicacco, Nicholas Zeitler, Kristen Montero, Jose Kumar, Ambuj Lakshmi, Seetha Kim, Kami Wein, David Vasey, Tiffany Vasey, Matthew Oxner, Asa |
author_facet | Piccicacco, Nicholas Zeitler, Kristen Montero, Jose Kumar, Ambuj Lakshmi, Seetha Kim, Kami Wein, David Vasey, Tiffany Vasey, Matthew Oxner, Asa |
author_sort | Piccicacco, Nicholas |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) continues to stress the health care system. Neutralizing monoclonal antibodies (mAbs) were effective in reducing COVID-19–related hospitalizations and emergency department (ED) visits in their respective clinical trials. However, these results have yet to be reproduced in a practical setting following implementation of current US Food and Drug Administration (FDA) guidance. METHODS: This retrospective cohort study included outpatients with confirmed COVID-19 infection, who had mild/moderate symptoms for 10 days or less, and who were deemed high-risk for severe COVID-19 under FDA’s Emergency Use Authorization for mAbs. Patients who received either bamlanivimab or casirivimab/imdevimab from 18 November 2020 through 5 January 2021 were included (n = 200). This was compared against a control cohort of randomly selected high-risk COVID-19 outpatients who declined or were not referred for mAb treatment during the same period (n = 200). The primary outcome was a composite of 29-day COVID-19–related hospitalizations and/or ED visits. Prespecified secondary outcomes included the individual components of the primary endpoint, 29-day all-cause mortality, and serious adverse drug events. RESULTS: Patients treated with mAbs were significantly less likely to be hospitalized or visit the ED compared with patients not treated with mAb (13.5% vs 40.5%; odds ratio, 0.23 [95% confidence interval, .14–.38]; P < .001). The mortality rate was 0% in the mAb group compared with 3.5% in the control group (P = .02). Only 2 patients receiving mAb experienced a serious adverse event requiring treatment. CONCLUSIONS: Among high-risk COVID-19 outpatients with mild/moderate symptoms, early administration of mAbs can potentially reduce the strain on the health care system during the current pandemic. |
format | Online Article Text |
id | pubmed-8195104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-81951042021-06-15 Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients Piccicacco, Nicholas Zeitler, Kristen Montero, Jose Kumar, Ambuj Lakshmi, Seetha Kim, Kami Wein, David Vasey, Tiffany Vasey, Matthew Oxner, Asa Open Forum Infect Dis Major Article BACKGROUND: Coronavirus disease 2019 (COVID-19) continues to stress the health care system. Neutralizing monoclonal antibodies (mAbs) were effective in reducing COVID-19–related hospitalizations and emergency department (ED) visits in their respective clinical trials. However, these results have yet to be reproduced in a practical setting following implementation of current US Food and Drug Administration (FDA) guidance. METHODS: This retrospective cohort study included outpatients with confirmed COVID-19 infection, who had mild/moderate symptoms for 10 days or less, and who were deemed high-risk for severe COVID-19 under FDA’s Emergency Use Authorization for mAbs. Patients who received either bamlanivimab or casirivimab/imdevimab from 18 November 2020 through 5 January 2021 were included (n = 200). This was compared against a control cohort of randomly selected high-risk COVID-19 outpatients who declined or were not referred for mAb treatment during the same period (n = 200). The primary outcome was a composite of 29-day COVID-19–related hospitalizations and/or ED visits. Prespecified secondary outcomes included the individual components of the primary endpoint, 29-day all-cause mortality, and serious adverse drug events. RESULTS: Patients treated with mAbs were significantly less likely to be hospitalized or visit the ED compared with patients not treated with mAb (13.5% vs 40.5%; odds ratio, 0.23 [95% confidence interval, .14–.38]; P < .001). The mortality rate was 0% in the mAb group compared with 3.5% in the control group (P = .02). Only 2 patients receiving mAb experienced a serious adverse event requiring treatment. CONCLUSIONS: Among high-risk COVID-19 outpatients with mild/moderate symptoms, early administration of mAbs can potentially reduce the strain on the health care system during the current pandemic. Oxford University Press 2021-06-04 /pmc/articles/PMC8195104/ /pubmed/34258319 http://dx.doi.org/10.1093/ofid/ofab292 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Piccicacco, Nicholas Zeitler, Kristen Montero, Jose Kumar, Ambuj Lakshmi, Seetha Kim, Kami Wein, David Vasey, Tiffany Vasey, Matthew Oxner, Asa Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients |
title | Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients |
title_full | Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients |
title_fullStr | Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients |
title_full_unstemmed | Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients |
title_short | Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients |
title_sort | effectiveness of severe acute respiratory syndrome coronavirus 2 monoclonal antibody infusions in high-risk outpatients |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195104/ https://www.ncbi.nlm.nih.gov/pubmed/34258319 http://dx.doi.org/10.1093/ofid/ofab292 |
work_keys_str_mv | AT piccicacconicholas effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT zeitlerkristen effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT monterojose effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT kumarambuj effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT lakshmiseetha effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT kimkami effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT weindavid effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT vaseytiffany effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT vaseymatthew effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients AT oxnerasa effectivenessofsevereacuterespiratorysyndromecoronavirus2monoclonalantibodyinfusionsinhighriskoutpatients |